Возможности оперативного лечения мочекаменной болезни у пациентов с хронической болезнью почек

Распространенность мочекаменной болезни, несмотря на успехи в ее лечении, возрастает в последние десятилетия. Хроническая болезнь почек является закономерным осложнением МКБ и поэтому также характеризуется тенденцией к увеличению распространенности. Это обусловило наш интерес к ХБП у пациентов с МКБ и подходам к оптимизации оптимальной тактики ведения пациентов. Произведен анализ современных источников литературы, рассмотрены эпидемиологические, патогенетические и клинические аспекты особенностей течения ХБП на фоне МКБ. Сформулированы практические рекомендации.

1. Alhamad T. Nephrology. Subspecialty Consult. Editors Tarek Alhamad, Steven Cheng, Anitha Vijayan. Washington, University in Stlouis, 2021, 485 p. eISBN: 978-1-975113-47-6

2. Johnson RJ, Floege J, Tonelli M. Comprehensive Clinical Nephrology. Seventh Edition. Elsevier, 2024, 1309 p. ISBN: 978-0323-82592-4

3. Chewcharat A, Curhan G. Trends in the prevalence of kidney stones in the United States from 2007 to 2016. Urolithiasis 2021;49(1):27–39

4. Ferraro PM, Unwin R, Bonny O, Gambaro G. Practice patterns of kidney stone management across European and non-European centers: an in-depth investigation from the European Renal Stone Network (ERSN). J Nephrol 2021;34(4):1337–1346. doi: 10.1007/S40620-020-00854-6

5. Brown Robert Stephen. Clinical handbook of nephrology.Elsevier, 2024, 313 p. ISBN: 978-0-323-84787-2

6. Bushinsky DA. Nephrolithiasis. In: Goldman S, ed. Goldman-Cecil, Medicine. Elsevier; 2020:776–781

7. Пак ЮГ, Ягудаев ДМ, Галлямов ЭА. Функциональной состояние почечной паренхимы после различных видеоэндохирургических методов лечения больных с крупными и сложными камнями. Хирургическая практика 2021;3(44):5–21. https://doi.org/10.38181/2223-2427-2021-3-5-21

8. Беспалова ИД, Бощенко ВС, Кощавцева ЮИ и др. Гендерные аспекты развития уролитиаза у пациентов с метаболическим синдромом. Бюллетень сибирской медицины 2021; 20 (4): 123–130. https://doi.org/10.20538/1682-0363-2021-4-123-130

9. Wilcox CR, Whitehurst LA, Somani BK, Cook P. Kidney stone disease: an update on its management in primary care. Br J Gen Pract 2020;70(693):205–206. doi: 10.3399/BJGP20X709277

10. Terence Kee Yi Shern. The Kidney Book. A Practical Guide on Renal Medicine. Editors: Terence Kee Yi Shern, Jason Choo Chon Jun, Woo Keng Thye. Tan Chieh Suai. World Scientific Publishing, Singapore, 2024, 869 p. ISBN 978-981-12-8422-9 (paperback)

11. Mustafa Arıcı. Management of Chronic Kidney Disease. A Clinician’s Guide. Second Edition. Editor Mustafa Arıcı. Switzerland AG, 2023, 603р. ISBN 978-3-031-42045-0 (eBook) https://doi.org/10.1007/978-3-031-42045-0

12. Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet 2021;398(10302):786–802. doi: 10.1016/S0140-6736(21)00519-5. Epub 2021 Jun 24. PMID: 34175022

13. Dhondup T, Kittanamongkolchai W, Vaughan LE, Mehta RA, Chhina JK, Enders FT, Rule AD (2018). Risk of ESRD and mortality in kidney and bladder stone formers. American Journal of Kidney Diseases 72(6):790–797. https://doi.org/10.1053/j.ajkd.2018.06.012

14. Schönauer R, Scherer L, Nemitz-Kliemchen M, Hagemann T, Hantmann E, Seidel A, Müller L, Kehr S, Voigt C, Stolzenburg J-U, Halbritter J (2022). Systematic assessment of monogenic etiology in adult-onset kidney stone formers undergoing urological intervention–evidence for genetic pretest probability. American Journal of Medical Genetics Part C: Seminars in Medical Genetics 190C:279–288. https://doi.org/10.1002/ajmg.c.31991

15. Uribarri J. Chronic kidney disease and kidney stones. Curr Opin Nephrol Hypertens 2020 Mar;29(2):237–242. doi: 10.1097/MNH.0000000000000582. PMID:31972597

16. Роюк РВ, Яровой СК. Хроническая болезнь почек у пациентов с рецидивирующим нефролитиазом и сопутствующим поражением сердечно-сосудистой системы. Вестник урологии 2021;9(3):52–61. doi: 10.21886/2308-6424-2021-9-3-52-613-52-61

17. Scurt FG, Ganz MJ, Herzog C, Bose K, Mertens PR, Chatzikyrkou C. Association of metabolic syndrome and chronic kidney disease. Obesity Reviews 2024;25(1):e13649. doi: 10.1111/obr.13649

18. Reisinger C, Nkeh-Chungag BN, Fredriksen PM, Goswami N. The prevalence of pediatric metabolic syndrome – a critical look on the discrepancies between definitions and its clinical importance. Int J Obes (Lond) 2021;45(1):12–24. doi: 10.1038/s41366-020-00713-1

19. Noubiap JJ, Nansseu JR, Lontchi-Yimagou E et al. Global, regional, and country estimates of metabolic syndrome burden in children and adolescents in 2020: a systematic review and modelling analysis. Lancet Child Adolesc Health 2022;6:158–170

20. Lee TH, Chen JJ, Wu CY, Yang CW, Yang HY. Hyperuricemia and progression of chronic kidney disease: a review from physiology and pathogenesis to the role of urate-lowering therapy. Diagnostics (Basel) 2021;11(9):11. doi: 10.3390/diagnostics11091674

21. Ramaswamy K, Shah O. Metabolic syndrome and nephrolithiasis. Transl Androl Urol 2014;3(3):285–295. doi: 10.3978/j.issn.2223-4683.2014.06.03

22. Роюк РВ, Яровой СК, Гусева НА и др. Эпидемиологические аспекты сочетания нефролитиаза и хронических заболеваний сердечно-сосудистой системы. Исследования и практика в медицине 2020; 7(1): 38–47. doi: 10.17709/2409-2231-2020-7-1-4

23. Goldfarb DS, Avery AR, Beara-Lasic L, Duncan GE, Goldberg J. A twin study of genetic influences on nephrolithiasis in women and men. Kidney International Reports 2019; 4(4), 535–540. https://doi.org/10.1016/j.ekir.2018.11.017

24. Daga A, Majmundar AJ, Braun DA, Gee HY, Lawson JA, Shril S,… Hildebrandt F. Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis. Kidney International 2018; 93(1): 204–213. https://doi.org/10.1016/j.kint.2017.06.025

25. Cogal AG, Arroyo J, Shah RJ, Reese KJ, Walton BN, Reynolds LM, … Investigators of the Rare Kidney Stone Consortium. Comprehensive genetic analysis reveals complexity of monogenic urinary stone disease. Kidney International Reports 2021;6(11): 2862–2884. https://doi.org/10.1016/j.ekir.2021.08.033

26. Zhao Y, Fang X, He L, Fan Y, Li Y, Xu G, … Geng H. A comparison of the clinical characteristics of pediatric urolithiasis patients with positive and negative molecular diagnoses. World Journal of Urology 2022;40:1211–1216. https://doi.org/10.1007/s00345-022-03934-3

27. Howles SA, Thakker RV. Genetics of kidney stone disease. Nat Rev Urol 2020;17(7):407–421. doi:10.1038/S41585-0200332-X

28. Sun BB, Kurki MI, Foley CN, Mechakra A, Chen CY, Marshall E, Runz H. Genetic associations of protein-coding variants in human disease. Nature 2022;603(7899):95–102. https://doi.org/10.1038/s41586-022-04394-w

29. Chang C-W, Ke H-L, Lee J-I, Lee YC, Jhan JH, Wang HS, …Geng JH. Metabolic syndrome increases the risk of kidney stone disease: A cross-sectional and longitudinal cohort study. Journal of Personalized Medicine 2021; 11(11): 1154. https://doi.org/10.3390/jpm11111154

30. Rahman IA, Nusaly IF, Syahrir S, Nusaly H, Mansyur MA. Association between metabolic syndrome components and the risk of developing nephrolithiasis: A systematic review and bayesian metaanalysis. F1000Res 2021;10:104. https://doi.org/10.12688/f1000research.28346.1

31. Kim SH, Rhee Y, Kim YM et al. Prevalence and complications of nonsurgical hypoparathyroidism in Korea: a nationwide cohort study. PLOS One 2020;15(5):e0232842

32. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int 2021;99(3S):S1–S87. doi: 10.1016/J.KINT.2020.11.003

33. Rejnmark L, Ayodele O, Lax A, Mu F, Swallow E, Gosmanova EO. The risk of chronic kidney disease development in adult patients with chronic hypoparathyroidism treated with rhPTH(1–84): a retrospective cohort study. Clin Endocrinol (Oxf) 2023;98:496–504. doi: 10.1111/cen.14813

34. Witting C, Langman CB, Assimos D et al. Pathophysiology and treatment of enteric hyperoxaluria. Clin J Am Soc Nephrol 2021;16(3):487–495. doi: 10.2215/CJN.08000520

35. Shee K, Stoller ML. Perspectives in primary hyperoxaluria—historical, current and future clinical interventions. Nat Rev Urol 2022;19(3):137–146. doi: 10.1038/S41585-021-00543-4

36. Burns Z, Knight J, Fargue S, Holmes R, Assimos D, Wood K. Future treatments for hyperoxaluria. Curr Opin Urol 2020;30(2):171. doi: 10.1097/MOU.0000000000000709

37. Alexander RT, Fuster DG, Dimke H. Mechanisms underlying calcium nephrolithiasis. Annu Rev Physiol 2022;84:559–583. doi: 10.1146/ANNUREV-PHYSIOL-052521-121822

38. Рунова ГЕ, Пешева ЕД, Вастистова AA и др. Гиперкальциемия с развитием хронической болезни почек, нефролитиаза после введения масляных растворов в мышцы. Остеопороз и остеопатии 2023; 26(3):33–39. https://doi.org/10.14341/osteo13141

39. Dhayat NA, Faller N, Bonny O et al. Efficacy of standard and low dose hydrochlorothiazide in the recurrence prevention of calcium nephrolithiasis (NOSTONE trial): protocol for a randomized double-blind placebo-controlled trial. BMC Nephrol 2018;19(1):349. doi: 10.1186/s12882-018-1144-6

40. Howles SA, Wiberg A, Goldsworthy M, Bayliss AL, Gluck AK, Ng M, … Furniss D. Genetic variants of calcium and vitamin D metabolism in kidney stone disease. Nature Communications 2019; 10(1):5175. https://doi.org/10.1038/s41467-019-13145-x

41. Irzyniec T, Boryn´ M, Kasztalska J, Nowak-Kapusta Z, Maciejewska-Paszek I, Grochowska-Niedworok E. The effect of an oral sodium phosphate load on parathyroid hormone and fibroblast growth factor 23 secretion in normo- and hypercalciuric stoneforming patients. Clin Nutr 2020;39(12):3804–3812. doi: 10.1016/J.CLNU.2020.04.020

42. Youssef RF, Martin JW, Sakhaee K et al. Rising occurrence of hypocitraturia and hyperoxaluria associated with increasing prevalence of stone disease in calcium kidney stone formers. Scand J Urol 2020;54(5):426–430. doi: 10.1080/21681805.2020.1794955.

43. Tang P-K, Jepson RE, Chang Y-M, Geddes RF, Hopkinson M, Elliott J. Risk factors and implications associated with renal mineralization in chronic kidney disease in cats. J Vet Intern Med 2022;36(2):634–646. doi: 10.1111/jvim.16363

44. Singh P, Harris PC, Sas DJ, Lieske JC. The genetics of kidney stone disease and nephrocalcinosis. Nat Rev Nephrol 2022;18(4):224–240. doi:10.1038/s41581-021-00513-4

45. Ходырева ЛА, Стародубова АВ, Соловьев ВВ и др. Уратный нефролитиаз: диагностика, лечение. Труды Научно-исследовательского института организации здравоохранения и медицинского менеджмента: Сборник научных трудов. Выпуск 7. М.: Государственное бюджетное учреждение города Москвы «Научно-исследовательский институт организации здравоохранения и медицинского менеджмента Департамента здравоохранения города Москвы», 2021:210–225. EDN CCPHMU

46. Huynh LM, Dianatnejad S, Tofani S et al. Metabolic diagnoses of recurrent stone formers: temporal, geographic and gender differences. Scand J Urol 2020;54(6):456–462. doi: 10.1080/21681805.2020.1840430

47. Rao IR, Bangera A, Nagaraju SP, Shenoy SV, Prabhu RA, Rangaswamy D et al. Chronic kidney disease of unknown aetiology: A comprehensive review of a global public health problem. Trop Med Int Health 2023;28(8):588–600. https://doi.org/10.1111/tmi.13913

48. Moe OW, Xu LHR. Hyperuricosuric calcium urolithiasis. J Nephrol 2018;31(2):189–196. doi: 10.1007/S40620-018-0469-3

49. Adomako E, Moe OW. Uric acid and urate in urolithiasis: the innocent bystander, instigator, and perpetrator. Semin Nephrol 2020;40(6):564–573. doi: 10.1016/j.semnephrol.2020.12.003

50. Zheng WW, Zhou Q, Xue ML, Yu X, Chen JT, Ao L, Wang CD. Association between inflammatory bowel disease, nephrolithiasis, tubulointerstitial nephritis, and chronic kidney disease: A propensity score-matched analysis of US nationwide inpatient sample 2016–2018. J Dig Dis 2023 Nov;24(11):572–583. doi: 10.1111/1751-2980.13233. Epub 2023 Nov 14. PMID: 37823607

51. Eisner BH, Goldfarb DS, Baum MA et al. Evaluation and medical management of patients with cystine nephrolithiasis: a consensus statement. J Endourol 2020;34(11):1103–1110. doi: 10.1089/END.2019.0703

52. Moore SL, Cook P, de Coninck V et al. Outcomes and longterm follow-up of patients with cystine stones: a systematic review. Curr Urol Rep 2019;20(6):27. doi: 10.1007/S11934-019-0891-7

53. Nazzal L, Blaser MJ. Does the receipt of antibiotics for common infectious diseases predispose to kidney stones? A cautionary note for all health care practitioners. J Am Soc Nephrol 2018;29(6):1590–1592

54. Tasian GE, Jemielita T, Goldfarb DS et al. Oral antibiotic exposure and kidney stone disease. J Am Soc Nephrol 2018;29(6): 1731–1740

55. Santoriello D, Al-Nabulsi M, Reddy A, Salamera J, D’Agati VD, Markowitz GS. Atazanavir-associated crystalline nephropathy. Am J Kidney Dis 2017;70(4):576–580. doi: 10.1053/J.AJKD.2017.02.376

56. Daudon M, Frochot V, Bazin D, Jungers P. Drug-induced kidney stones and crystalline nephropathy: pathophysiology, prevention and treatment. Drugs 2018;78(2):163–201. doi: 10.1007/S40265-017-0853-7

57. Moore CL, Bhargavan-Chatfield M, Shaw MM, Weisenthal K, Kalra MK. Radiation dose reduction in kidney stone CT: a randomized, facility-based intervention. J Am Coll Radiol 2021;18(10):1394–1404. doi: 10.1016/J.JACR.2021.05.004

58. Servais A, Thomas K, Dello Strologo L et al. Cystinuria: clinical practice recommendation. Kidney Int 2021; 99(1):48–58. doi: 10.1016/J.KINT.2020.06.035

59. Abu-Ghanem Y, Kleinmann N, Erlich T, Winkler HZ, Zilberman DE. The impact of dietary modifications and medical management on 24-hour urinary metabolic profiles and the status of renal stone disease in recurrent stone formers. Isr Med Assoc J 2021;23(1):12–16

60. Борисов ВВ, Шилов ЕМ. Литолитическая терапия при уратном нефролитиазе (клиническая лекция). Нефрология 2016; 20(4):107–112

61. Medina-Escobedo M, Sánchez-Pozos K, GutiérrezSolis AL, Avila-Nava A, González-Rocha L, Lugo R. Recurrence of Nephrolithiasis and Surgical Events Are Associated with Chronic Kidney Disease in Adult Patients. Medicina (Kaunas) 2022 Mar 12;58(3):420. doi: 10.3390/medicina58030420. PMID: 35334596; PMCID:PMC8954899

62. Chuang TZ, Hung HC, Li SF et al. Risk of chronic kidney disease in patients with kidney stones – a nationwide cohort study. BMC Nephrol 2020;21:292–298

63. Kim CH, Chung DY, Rha KH, Lee JY, Lee SH. Effectiveness of percutaneous nephrolithotomy, retrograde intrarenal surgery, and extracorporeal shock wave lithotripsy for treatment of renal stones: a systematic review and meta-analysis. Medicina (Kaunas) 2020;57(1):1–23. doi: 10.3390/MEDICINA57010026

64. Пак ЮГ, Ягудаев ДМ. Влияние эндовидеоскопических операций при нефролитиазе на функциональное состояние почек. Экспериментальная и клиническая урология 2022;15(1):85–89. https://doi.org/10.29188/2222-8543-202215-1-85-89

65. Попов СВ, Гусейнов РГ, Милосердов ИА, Кисиль ЮВ и др. Эффективность дистанционной ударно-волновой литотрипсии камней трансплантированной почки. Надежда или разочарование? Вестник трансплантологии и искусственных органов 2023; 25(3): 57–63. doi: 10.15825/1995-1191-2023-3-57-63

66. Tsai SH, Chung HJ, Tseng PT et al. Comparison of the efficacy and safety of shockwave lithotripsy, retrograde intrarenal surgery, percutaneous nephrolithotomy, and minimally invasive percutaneous nephrolithotomy for lower-pole renal stones: a systematic review and network meta-analysis. Medicine (Baltimore) 2020;99(10):e19403. doi: 10.1097/MD.0000000000019403

67. Veser J, Jahrreiss V, Seitz C. Innovations in urolithiasis management. Curr Opin Urol 2021;31(2):130–134. doi: 10.1097/MOU.0000000000000850

68. Ansari FM, Para SA, Wani MS, Bhat AH, Khawaja AR, Malik SA, Mehdi S, Ashraf W, Singh S, Maurya M, Mushtaq A. MiniPCNL – a boon for CKD patients with nephrolithiasis. Arab J Urol 2023 Dec 26;22(2):115–120. doi: 10.1080/20905998.2023.2295041. PMID: 38481409; PMCID: PMC10929665

69. Shah TT, Gao C, Peters M et al. British Urology Researchers in Surgical Training (BURST) Collaborative MIMIC Study Group. Factors associated with spontaneous stone passage in a contemporary cohort of patients presenting with acute ureteric colic: results from the Multi-centre cohort study evaluating the role of Inflammatory Markers in patients presenting with acute ureteric Colic (MIMIC) study. BJU Int 2019;124(3):504–513

70. Turk C (Chair), Neisius A, Petrik A et al. European Association of Urology Guidelines on Urolithiasis; 2020. www.uroweb.org/guideline/urolithiasis

71. Чухловин АБ, Эмануэль ЮВ, Напалкова ОВ, Ланда СБ, Эмануэль ВЛ. Роль локальных инфекций в генезе мочекаменной болезни. Нефрология 2011;15(3):11–17. https://doi.org/10.24884/1561-6274-2011-15-3-11-17

72. Bravi CA, Larcher A, Capitanio U et al. Perioperative outcomes of open, laparoscopic, and robotic partial nephrectomy: a prospective multicenter observational study (the RECORd 2 project). Eur Urol Focus 2021;7(2):390–396. https://doi.org/10.1016/j.euf.2019.10.013. Epub 2019 Nov 12. PMID: 31727523

73. Zhuo M, Yang D, Goldfarb-Rumyantzev A, Brown RS. The association of SBP with mortality in patients with stage 1–4 chronic kidney disease. J Hypertens 2021;39(11):2250–2257. doi: 10.1097/hjh.0000000000002927

74. Wright EM. SGLT2 inhibitors: physiology and pharmacology. Kidney360 2021;2(12):2027–2037. doi:10.34067/KID.0002772021

75. Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet 2021;398(10296):262–276. doi: 10.1016/S0140-6736(21)00536-5

76. Bakris GL, Agarwal R, Anker SD et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020;383(23):2219–2229. doi: 10.1056/NEJMOA2025845

77. Portolés J, Martín L, Broseta JJ, Cases A. Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents. Front Med (Lausanne) 2021;8:642296. doi: 10.3389/FMED.2021.642296

78. Babitt JL, Eisenga MF, Haase VH et al. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int 2021;99(6):1280–1295. doi: 10.1016/J.KINT.2021.03.020

79. Wish JB. Treatment of anemia in kidney disease: beyond erythropoietin. Kidney Int Rep 2021;6(10):2540–2553. doi: 10.1016/J.EKIR.2021.05.028

80. Hahn D, Hodson EM, Fouque D. Low protein diets for nondiabetic adults with chronic kidney disease. Cochrane Database Syst Rev 2020;10(10):CD001892. doi: 10.1002/14651858.CD001892.pub5

81. Molina P, Gavela E, Vizcaíno B, Huarte E, Carrero JJ. Optimizing diet to slow CKD progression. Front Med (Lausanne) 2021;8:654250. doi: 10.3389/FMED.2021.654250

82. Mills KT, Chen J, Yang W, et al. Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease. JAMA 2016;315(20):2200–2210. doi: 10.1001/jama.2016.4447

83. Raphael KL. Metabolic acidosis in CKD: core curriculum 2019. Am J Kidney Dis 2019;74(2):263–275. doi: 10.1053/J.AJKD.2019.01.036

84. Madias NE. Metabolic acidosis and CKD progression. Clin J Am Soc Nephrol 2021;16(2):310–312. doi: 10.2215/CJN.07990520